Fig. 2From: Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from ChinaCA125 values in each group. Note: The CA125 level of the first follow-up was used as the reference value, and all data were converted to natural logarithm. CA125 follow-up data were obtained from 2 patient in the first-line maintenance treatment group, 10 patients in the second-line maintenance treatment group, 6 patients in the multi-line therapy group, and 10 patients in the exploratory therapy groupBack to article page